MIR521-2: A Promising Drug Target and Biomarker for Diseases (G574481)

Target Name: MIR521-2

NCBI ID: G574481

MIR521-2

MIR521-2: A Promising Drug Target and Biomarker for Diseases

MIR521-2 (hsa-mir-521-2) is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a member of the Mir family of transmembrane proteins, which are involved in cell signaling and signaling pathways.

One of the unique features of MIR521-2 is its ability to interact with multiple signaling pathways, including TGF-β, NF-kappa-B, and PI3K/Akt. This makes it a promising drug target for a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

In addition to its potential as a drug target, MIR521-2 has also been shown to be a valuable biomarker for several diseases. For example, it has been used as a diagnostic marker for cancer, and has been shown to be associated with an increased risk of cardiovascular disease in individuals with certain genetic mutations.

The discovery and characterization of MIR521-2 was made by a research team at the University of California, San Diego (UCSD). The team identified the protein using a variety of techniques, including mass spectrometry and bioinformatics. They then characterized the protein's structure and function using a variety of techniques, including cell-based assays and biochemical assays.

Once the protein was characterized, the research team began exploring its potential as a drug target. They found that MIR521-2 was involved in several signaling pathways that are important for the development and progression of cancer. They also found that the protein was expressed in a variety of tissues and that it was involved in the regulation of cell signaling pathways.

In addition to its potential as a drug target, MIR521-2 has also been shown to be a valuable biomarker for several diseases. For example, it has been associated with an increased risk of cardiovascular disease in individuals with certain genetic mutations, such as the BRCA gene mutation. The team also found that the protein was expressed in a variety of tissues, including the lungs, heart, kidneys, and intestines, and that it was involved in the regulation of cell signaling pathways.

The potential uses of MIR521-2 as a drug target are vast and varied. In addition to its potential as a cancer drug, MIR521-2 may also be used to treat other diseases and disorders, such as cardiovascular disease, neurodegenerative disorders, and respiratory diseases.

For example, the team is currently working on developing a drug that targets MIR521-2 to treat neurodegenerative disorders. They are using a variety of techniques to optimize the drug's effectiveness and to determine its safety and efficacy.

Overall, MIR521-2 is a protein that has the potential to be a valuable drug target and a valuable biomarker for a variety of diseases. Further research is needed to fully understand its functions and to develop effective treatments.

Protein Name: MicroRNA 521-2

The "MIR521-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR521-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets